Columbia Funds Series Trust I - Columbia Contrarian Core Fund

The investment seeks total return, consisting of long-term capital appreciation and current income. Under normal circumstances, the fund invests at least 80% of its net assets (including the amount of any borrowings for investment purposes) in common stocks. In addition, under normal circumstances, it invests at least 80% of its net assets in equity securities of U.S. companies that have large market capitalizations (generally over $2 billion) that the fund's investment manager believes are undervalued and have the potential for long-term growth and current income. The fund may also invest up to 20% of its net assets in foreign securities.

Columbia Funds Series Trust I - Columbia Contrarian Core Fund trades as COFYX on NASDAQ. The company is classified in Financial Services / Asset Management and reports in USD.

The current profile places the business in Asset Management. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Columbia Funds Series Trust I - Columbia Contrarian Core Fund can be compared against peers such as AB Large Cap Growth Fund Class I, American Funds Moderate Growth and Income Portfolio - Class F-1, Causeway International Value Fund Class Institutional, Columbia Fds Srs Tr I, Strategic Income Fd Cl A, American Funds 2020 Target Date Retirement Fd Cl F-1, MFS Mid Cap Growth Fund Class R6.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $17.96B, beta of 1.01, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

COFYX currently shows total debt of N/A and beta of 1.01. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: N-CSR (2026-06-04 00:00:00), 40-17F2 (2026-05-29 00:00:00), 40-17F2 (2026-05-29 00:00:00), NPORT-P (2026-05-28 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.columbiathreadneedleus.com/investment-products/mutual-funds/columbia-contrarian-core-fund/class-institutional3/details?cusip=19766M709

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.